| DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-19 |
| DeuterOncology–Investsud: investment, 202301 financing round Series A toatlling €5.65m incl new investor Investsud Tech |
2023-01-19 |
| DeuterOncology–Newton Biocapital: investment, 202301 financing round Series A toatlling €5.65m incl existing investor Newton Biocapital |
2023-01-19 |
| DeuterOncology–Noshaq: investment, 202301 financing round Series A toatlling €5.65m incl new investor Noshaq |
2023-01-19 |
| DeuterOncology–SEVERAL: investment, 202301 financing round Series A €5.65m with Newton Biocapital + Noshaq + Investsud Tech |
2023-01-19 |
| Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash |
2023-01-09 |
| Hummingbird Bioscience–Synaffix: ADC technology, 202301– license to GlycoConnect + HydraSpace + toxSYN technoligies up to $150m plus royalties |
2023-01-04 |
| Affibody–EU (govt): credit, 202212– venture debt loan facility €20m from EIB supported by InvestEU programme |
2022-12-22 |
| Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB |
2022-12-20 |
| Numares–SEVERAL: investment, 202212 financing round €20m from existing investors |
2022-12-20 |
| S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG |
2022-12-16 |
| Minervax–EU (govt): credit, 202212 loan facility €50m from EIB |
2022-12-15 |
| ExeVir Bio–EU (govt): credit, 202212– venture debt financing €25m from EIB for develoment of nanobody Covid-19 therapy |
2022-12-14 |
| Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures |
2022-12-14 |
| Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC |
2022-12-14 |
| MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM |
2022-12-08 |
| Neogene Therapeutics–AstraZeneca: investment, 202211–202301 acquisition $200m upfront + $120 milestones on cash/debt free basis |
2022-11-29 |
| Biomemory–eureKARE: investment, 202211 seed financing round totalling €5m incl co-lead investor eureKARE |
2022-11-28 |
| Biomemory–France (govt): investment, 202211 seed financing round totalling €5m incl co-lead investor French Tech Seed Fund |
2022-11-28 |
| Biomemory–SEVERAL: investment, 202211 seed financing round €5m led by eureKARE + French Tech Seed Fund |
2022-11-28 |
| Hemispherian–Meneldor: investment, 202211 financing round Series A1 first tranche totalling NOK30m ($2.9m) incl existing + lead investor Meneldor |
2022-11-24 |
| Hemispherian–SEVERAL: investment, 202211 financing round Series A1 first tranche of NOK30m ($2.9m) led by Meneldor |
2022-11-24 |
| Catalym–BioGeneration Ventures: investment, 202211 financing round Series C totalling €50m incl existing + co-investor BGV |
2022-11-22 |
| Catalym–Forbion: investment, 202211 financing round Series C totalling €50m incl existing + co-investor Forbion |
2022-11-22 |
| Catalym–Germany (govt): investment, 202211 financing round Series C totalling €50m incl existing + co-investor Coparion |
2022-11-22 |
| Catalym–SEVERAL: investment, 202211 financing round Series C €50m led by Brandon Capital + Jeito Capital |
2022-11-22 |
| Catalym–Vesalius Biocapital: investment, 202211 financing round Series C totalling €50m incl existing + co-investor Vesalius Biocapital III |
2022-11-22 |
| Cradle Bio–Index Ventures: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Index Ventures |
2022-11-17 |
| Cradle Bio–Kindred Capital: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Kindred Capital |
2022-11-17 |
| Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Emily LeProust |
2022-11-17 |
| Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Feike Sijbesma |
2022-11-17 |
| Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Sylvain Gariel |
2022-11-17 |
| Cradle Bio–SEVERAL: investment, 202211 emerges from stealth with €5.5m seed financing round led by Index Ventures + Kindred Capital |
2022-11-17 |
| FundaMental Pharma–SEVERAL: investment, 202211 seed financing round €10m led by BGV + Thuja Capital |
2022-11-17 |
| Enzyre–SEVERAL: investment, 202211 financing round Series A €12m (incl Dutch Govt Innovation Credit) led by Oost NL |
2022-11-02 |
| Resolve Biosciences–SEVERAL: investment, 202210 financing round Series B $71m led by Patient Square Capital |
2022-10-24 |
| VIB–Resolve Biosciences: Molecular Cartography technology, 202210 supply to VIB existent as one of first customers |
2022-10-24 |
| Enhanc3D Genomics–Bioqube Ventures: investment, 202210 financing round Series A totalling £10m incl existing + co-investor Bioqube Ventures |
2022-10-20 |
| Enhanc3D Genomics–SEVERAL: investment, 202210 financing round Series A £10m led by BGF + Parkwalk Advisors |
2022-10-20 |
| Nucleome Therapeutics–Merck (DE): investment, 202210 financing round Series A totalling £37.5m incl new + lead investor M Ventures |
2022-10-19 |
| Nucleome Therapeutics–SEVERAL: investment, 202210 financing round Series A £37.5m led by M Ventures |
2022-10-19 |
| Orionis Biosciences–SEVERAL: investment, 202210 financing round $55m with Cormorant AM + Novartis et al |
2022-10-19 |
| Univercells–SEVERAL: investment, 202210 financing round Series D 1st closing €44m with SFPI-FPIM + SRIW et al |
2022-10-19 |
| Mablink Bioscience–Fournier-Majoie Foundation: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Fondation FM |
2022-10-14 |
| Mablink Bioscience–SEVERAL: investment, 202210 financing round Series A €31m led by Sofinnova Partners + Mérieux Equity Partners |
2022-10-14 |
| Andera Partners–SEVERAL: investment, 202210 final closing of BioDiscovery 6 fund at €456m |
2022-10-10 |
| Immatics–SEVERAL: investment, 202210 underwritten offering $110m with 10.9m ordinary shares at $10.09/share |
2022-10-10 |
| Crainio–NLC Ventures: investment, 202210 existent seed investor NLC |
2022-10-05 |
| Araris Biotech–SEVERAL: investment, 202210 financing round $24m co-led by 4BIO Capital + Pureos Bioventures |
2022-10-04 |
| Sibylla Biotech–SEVERAL: investment, 202210 financing round Series A €23m led by V-Bio Ventures |
2022-10-04 |
| Sibylla Biotech–V-Bio Ventures: investment, 202210 financing round Series A totalling €23m incl lead investor V-Bio Ventures |
2022-10-04 |
| BioDGraft–NLC Ventures: investment, 202209 existent seed investor NLC |
2022-09-27 |
| EFOS (SI)–ECBF: investment, 202209 financing round Series B totalling €10m incl lead investor European Circular Bioeconomy Fund |
2022-09-20 |
| EFOS (SI)–SEVERAL: investment, 202209 financing round Series B €10m led by ECBF |
2022-09-20 |
| Kuros–Alpha Capital: investment, 202209 capital increase totalling CHF6m incl investor Pegasus Global Opportunity Fund Ltd |
2022-09-15 |
| Kuros–Optiverder: investment, 202209 capital increase totalling CHF6m incl investor Optiverder BV |
2022-09-15 |
| Kuros–SEVERAL: investment, 202209 capital increase CHF6m via private placement with 3.75m new shares at CHF1.6/share |
2022-09-15 |
| Tridek-One–Bioqube Ventures: investment, 202209 2nd financing round totalling €16m incl new + co-investor Bioqube Ventures |
2022-09-15 |
| Tridek-One–SEVERAL: investment, 202209 2nd financing round €16m led by Pureos Bioventures |
2022-09-15 |
| Standing Ovation–Astanor Ventures: investment, 202209 financing round Series A totalling €12m incl lead investor Astanor Ventures |
2022-09-14 |
| Standing Ovation–SEVERAL: investment, 202209 financing round Series A €12m lead by Astanor Ventures |
2022-09-14 |
| Sanquin–Gilde Investment: investment, 202208– acquisition of Sanquin Reagents from SHS by GHPE IV ANNOUNCED |
2022-08-29 |
| eTheRNA–China Grand Pharma: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Grand Pharma |
2022-08-23 |
| eTheRNA–EQT: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor EQT Life Sciences (formerly LSP) |
2022-08-23 |
| eTheRNA–Flanders (govt): investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor PMV |
2022-08-23 |
| eTheRNA–Fund+: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Fund+ |
2022-08-23 |
| eTheRNA–Novalis LifeSciences: investment, 202208 financing round Series B2 totalling €39m incl existing + lead investor Novalis LifeSciences LLC |
2022-08-23 |
| eTheRNA–Omega Funds: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Omega Fund |
2022-08-23 |
| eTheRNA–PERSON: investment, 202208 financing round Series B2 totalling €39m incl new + co-investor Kenneth Chien |
2022-08-23 |
| eTheRNA–SEVERAL: investment, 202208 financing round Series B2 €39m led by existing investor Novalis LifeSciences LLC |
2022-08-23 |
| Genome Diagnostics–Eurobio Scientific: investment, 202208– acquisition 100% of GenDx for €135m in cash (net of adjusted cash) |
2022-08-17 |
| B Medical Systems–Azenta: investment, 202208–202210 acquisition $410m upfront + $50m milestones 100% of B Medical from Navis Capital |
2022-08-08 |
| F2G Ltd–Forbion: investment, 202208 financing round totalling $70m inc new + co-lead investor Forbion |
2022-08-04 |
| F2G Ltd–Novo Group: investment, 202208 financing round totalling $70m inc existing + co-investor Novo Holdings |
2022-08-04 |
| F2G Ltd–SEVERAL: investment, 202208 financing round $70m co-led by new investors Forbion + Sofinnova Partners |
2022-08-04 |
| Haermonics–SEVERAL: investment, 202208 financing round Series C €4.3m led by BOM + Demcon + Stepping Stone/NLC |
2022-08-02 |
| SHS Capital–EU (govt): investment, 202207 first closing totalling over €220m of SHS VI fund incl investor EIF |
2022-07-18 |
| SHS Capital–SEVERAL: investment, 202207 first closing at over €220m of SHS VI fund with EIF + Realdania + Helsana HealthInvest + LBBW et al. |
2022-07-18 |
| Agomab Therapeutics–Asabys Partners: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Asabys Partners |
2022-07-13 |
| Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors |
2022-07-13 |
| Agomab Therapeutics–Pfizer: investment, 202207 financing round Series B extension totalling $40.5m incl new + lead investor Pfizer Breakthrough GI |
2022-07-13 |
| Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m |
2022-07-13 |
| Agomab Therapeutics–Walleye Capital: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Walleye Capital |
2022-07-13 |
| Cergentis–Solvias: investment, 202207 acquisition €na of Cergentis by Solvias |
2022-07-12 |
| Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF |
2022-07-07 |
| Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF |
2022-07-07 |
| Phytolon–DSM: investment, 202207 financing round Series A totalling $14.5m incl new + lead investor DSM Venturing |
2022-07-07 |
| Phytolon–SEVERAL: investment, 202207 financing round Series A $14.5m led by DSM Venturing |
2022-07-07 |
| Menarini–NewAmsterdam Pharma: obicetrapib, 202206– license excl €115m upfront + €27.5m funding + €863m milestones for cardiovascular in Europe |
2022-06-28 |
| Verve Capital Partners–SEVERAL: investment, 202206 1st CHF45m closing of Verve Venture Fund I |
2022-06-24 |
| Abound Bio–Galapagos: investment, 202206 acquisition $14m in cash of AboundBio by Galapagos |
2022-06-21 |
| Carma Fund–EU (govt): investment, 202206 first closing totalling €47m of Carma Fund I incl investor EIF |
2022-06-21 |
| Carma Fund–SEVERAL: investment, 202206 first closing €47m of Carma Fund I with target size of €60m |
2022-06-21 |
| CellPoint–Galapagos: investment, 202206 acquisition in cash €125m upfront + €100m milestones of CellPoint by Galapagos |
2022-06-21 |
| JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica |
2022-06-14 |
| ImCheck Therapeutics–EQT: investment, 202206 financing round Series C totalling €80m incl existing + co-investor EQT Life Sciences |
2022-06-13 |
| ImCheck Therapeutics–Gimv: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Gimv |
2022-06-13 |
| ImCheck Therapeutics–SEVERAL: investment, 202206 financing round Series C €80m co-led by new investors Earlybird + Andera Partners |
2022-06-13 |
| ModuVision–Knauer: investment, 202206 acquisition of ModuVision by Knauer |
2022-06-13 |
| Forbion–SEVERAL: investment, 202206 first close €470m of Forbion Growth Opportunities Fund II with target size of €600m hard cap |
2022-06-09 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg){kind=tracking}
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
